1253383-92-4

Upstream product

• 82671-06-5 2,6-dichloro-5-fluoro-3-pyridinecarboxylic acid 
• 1253383-90-2 2-chloro-5-fluoro-6-methylnicotinic acid methyl ester 
• 189281-66-1 methyl 2,6-dichloro-5-fluoro-pyridine-3-carboxylate 
• 100-51-6 benzyl alcohol 
• 932705-78-7 5-fluoro-6-methylnicotinic acid 

Downstream Products

• 1211542-12-9 5-fluoro-6-methylpyridin-3-amine 

Relevant academic research and scientific papers

NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF

The object of the present invention is to provide a compound and a pharmaceutical composition having excellent Syk inhibitory activity. According to the present invention, a nicotinamide derivative represented by the following formula (I) or a salt thereof is provided, wherein R1 is a substituent represented by the following formula (II-1), (III-1), or (IV-1) (wherein R3, R4, R5, n, and X1 have the same definitions as those described in the specification), and R2 is a pyridyl, indazolyl, phenyl, pyrazolopyridyl, benzisoxazolyl, pyrimidinyl, or quinolyl group, each of which optionally has at least one substituent.

CXCR3 RECEPTOR ANTAGONISTS

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6, A, B, X, Y and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.